AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

Groundbreaking findings from Malaysia’s Heart2Miss heart failure screening programme were presented at the European Society ...

AstraZeneca Vietnam has been honoured in the Outstanding CSR Activities category at the 2025 Top 50 Corporate Sustainability ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

New class of Eureka Fellows selected for their outstanding efforts to build a healthier, more equitable world and will receive support to amplify their sustainability impact in Canada and around ...

In recent years successive governments have sought to close down free speech. If we are to avoid the enslavement of our ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives; namely, ...

DelveInsight's Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ ...